Kotzerke J, Bergmann K, Glatz S, Höher M, Reske S N
Abteilung Nuklearmedizin, Universität Ulm, Deutschland.
Nuklearmedizin. 1997 Jan;36(1):19-22.
Arbutamine is a new catecholamine that has been developed as a pharmacologic stress agent for the diagnosis of coronary artery disease. Optionally, it can be used in myocardial scintigraphy. The pharmacologic effect compared to dipyridamole was assessed looking at the whole body distribution of Tc-99m-Sestamibi.
9 patients were investigated after injection of Tc-99m-Sestamibi during rest, after infusion of arbutamine, and after vasodilatation with dipyridamole.
Infusion of arbutamine results in a measurable diminished radiotracer deposition in the lower limb as compared to dipyridamole. The amount of myocardial activity of Tc-99m-sestamibi, however, is also reduced as shown by the percentage of myocardial activity compared to the whole body distribution (2.5% +/- 0.4% for arbutamine vs. 2.8% = 0.5% for dipyridamole) in addition, the heart/lung ratio is lower after application of arbutamine (12.1% +/- 0.5% vs. 2.4% +/- 0.4%).
After infusion of arbutamine the percentage of myocardial activity as well as the contrast of the myocardium to the surrounding lungs is decreased as compared to dipyridamole. Further studies should reveal whether this difference is relevant in diagnosing coronary artery disease.
阿巴胺是一种新型儿茶酚胺，已被开发用作诊断冠状动脉疾病的药物应激剂。此外，它还可用于心肌闪烁显像。通过观察锝-99m-司他比的全身分布，评估其与双嘧达莫相比的药理作用。
对9名患者在静息状态下注射锝-99m-司他比后、输注阿巴胺后以及用双嘧达莫进行血管扩张后进行了研究。
与双嘧达莫相比，输注阿巴胺导致下肢放射性示踪剂沉积明显减少。然而，锝-99m-司他比的心肌活性也有所降低，这可通过心肌活性占全身分布的百分比来显示（阿巴胺为2.5%±0.4%，双嘧达莫为2.8%±0.5%）。此外，应用阿巴胺后心脏/肺比值较低（分别为12.1%±0.5%和12.4%±0.4%）。
与双嘧达莫相比，输注阿巴胺后心肌活性百分比以及心肌与周围肺组织的对比度均降低。进一步的研究应揭示这种差异在诊断冠状动脉疾病中是否具有相关性。
